Maja Guberina1, Wilfried Eberhardt2, Martin Stuschke3,4, Thomas Gauler1, Clemens Aigner5,6, Martin Schuler2,5, Georgios Stamatis6, Dirk Theegarten7, Walter Jentzen8, Ken Herrmann5,8, Christoph Pöttgen1. 1. Department of Radiation Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany. 2. Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, 45122, Essen, Germany. 3. Department of Radiation Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany. martin.stuschke@uk-essen.de. 4. German Cancer Consortium (DKTK), Partner Site University Hospital Essen, 45122, Essen, Germany. martin.stuschke@uk-essen.de. 5. German Cancer Consortium (DKTK), Partner Site University Hospital Essen, 45122, Essen, Germany. 6. Department of Thoracic Surgery, Ruhrlandklinik, University of Duisburg-Essen Medical School, 45239, Essen, Germany. 7. Department of Pathology, West German Cancer Center, University of Duisburg-Essen Medical School, 45122, Essen, Germany. 8. Department of Nuclear Medicine, West German Cancer Center, University of Duisburg-Essen Medical School, 45122, Essen, Germany.
Abstract
PURPOSE: According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by 18F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT, we analysed mature survival data from the German phase III trial ESPATUE. METHODS: This analysis included patients who were staged by PET/CT and who were enrolled in the ESPATUE trial, a randomized study comparing definitive RCT (arm A) with surgery (arm B) after induction chemotherapy and RCT in patients with resectable stage IIIA/IIIB NSCLC. Patients refusing surgery and those with nonresectable disease were scheduled to receive definitive RCT. MTV was measured using a fixed threshold-based approach and a model-based iterative volume thresholding approach. Data were analysed using proportional hazards models and Kaplan-Meier survival functions. RESULTS:MTV as a continuous variable did not reveal differences in survival between the 117 patients scheduled to receive definitive RCT and all 169 enrolled patients who underwentpretreatment PET/CT (p > 0.5). Five-year survival rates were 33% (95% CI 17-49%) in patients scheduled for definitive RCT with a high MTV (>95.4 ml) and 32% (95% CI: 22-42%) in those with a low MTV. The hazard ratio for survival was 0.997 (95% CI 0.973-1.022) per 10-ml increase in MTV and the slope was significantly shallower than that in the ACRIN 6668/RTOG 0235 trial (random effects model, p = 0.002). There were no differences in MTV size distributions between the ACRIN and ESPATUE trials (p = 0.97). CONCLUSION:Patients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
RCT Entities:
PURPOSE: According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by 18F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT, we analysed mature survival data from the German phase III trial ESPATUE. METHODS: This analysis included patients who were staged by PET/CT and who were enrolled in the ESPATUE trial, a randomized study comparing definitive RCT (arm A) with surgery (arm B) after induction chemotherapy and RCT in patients with resectable stage IIIA/IIIB NSCLC. Patients refusing surgery and those with nonresectable disease were scheduled to receive definitive RCT. MTV was measured using a fixed threshold-based approach and a model-based iterative volume thresholding approach. Data were analysed using proportional hazards models and Kaplan-Meier survival functions. RESULTS:MTV as a continuous variable did not reveal differences in survival between the 117 patients scheduled to receive definitive RCT and all 169 enrolled patients who underwent pretreatment PET/CT (p > 0.5). Five-year survival rates were 33% (95% CI 17-49%) in patients scheduled for definitive RCT with a high MTV (>95.4 ml) and 32% (95% CI: 22-42%) in those with a low MTV. The hazard ratio for survival was 0.997 (95% CI 0.973-1.022) per 10-ml increase in MTV and the slope was significantly shallower than that in the ACRIN 6668/RTOG 0235 trial (random effects model, p = 0.002). There were no differences in MTV size distributions between the ACRIN and ESPATUE trials (p = 0.97). CONCLUSION:Patients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
Entities:
Keywords:
Induction; MTV; NSCLC; Prognostic marker; Stage III
Authors: G Goeckenjan; H Sitter; M Thomas; D Branscheid; M Flentje; F Griesinger; N Niederle; M Stuschke; T Blum; K-M Deppermann; J H Ficker; L Freitag; A S Lübbe; T Reinhold; E Späth-Schwalbe; D Ukena; M Wickert; M Wolf; S Andreas; T Auberger; R P Baum; B Baysal; J Beuth; H Bickeböller; A Böcking; R M Bohle; I Brüske; O Burghuber; N Dickgreber; S Diederich; H Dienemann; W Eberhardt; S Eggeling; T Fink; B Fischer; M Franke; G Friedel; T Gauler; S Gütz; H Hautmann; A Hellmann; D Hellwig; F Herth; C P Heussel; W Hilbe; F Hoffmeyer; M Horneber; R M Huber; J Hübner; H-U Kauczor; K Kirchbacher; D Kirsten; T Kraus; S M Lang; U Martens; A Mohn-Staudner; K-M Müller; J Müller-Nordhorn; D Nowak; U Ochmann; B Passlick; I Petersen; R Pirker; B Pokrajac; M Reck; S Riha; C Rübe; A Schmittel; N Schönfeld; W Schütte; M Serke; G Stamatis; M Steingräber; M Steins; E Stoelben; L Swoboda; H Teschler; H W Tessen; M Weber; A Werner; H-E Wichmann; E Irlinger Wimmer; C Witt; H Worth Journal: Pneumologie Date: 2010-12-14
Authors: Thomas E Stinchcombe; David E Morris; Dominic T Moore; John H Bechtel; Jan S Halle; Andrea Mears; Katherine Deschesne; Julian G Rosenman; Mark A Socinski Journal: Lung Cancer Date: 2006-02-24 Impact factor: 5.705
Authors: Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Aalok P Patel; Traves D Crabtree; Jennifer M Bell; Tracey J Guthrie; Clifford G Robinson; Daniel Morgensztern; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; Jeffrey D Bradley; G Alexander Patterson; Bryan F Meyers; Varun Puri Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Patsuree Cheebsumon; Ronald Boellaard; Dirk de Ruysscher; Wouter van Elmpt; Angela van Baardwijk; Maqsood Yaqub; Otto S Hoekstra; Emile Fi Comans; Adriaan A Lammertsma; Floris Hp van Velden Journal: EJNMMI Res Date: 2012-10-03 Impact factor: 3.138
Authors: Tae Ryool Koo; Sung Ho Moon; Yu Jin Lim; Ja Young Kim; Yeonjoo Kim; Tae Hyun Kim; Kwan Ho Cho; Ji-Youn Han; Young Joo Lee; Tak Yun; Heung Tae Kim; Jin Soo Lee Journal: Radiat Oncol Date: 2014-12-13 Impact factor: 3.481
Authors: Maja Guberina; Christoph Poettgen; Martin Metzenmacher; Marcel Wiesweg; Martin Schuler; Clemens Aigner; Till Ploenes; Lale Umutlu; Thomas Gauler; Kaid Darwiche; Georgios Stamatis; Dirk Theegarten; Hubertus Hautzel; Walter Jentzen; Nika Guberina; Ken Herrmann; Wilfried E E Eberhardt; Martin Stuschke Journal: J Nucl Med Date: 2021-05-20 Impact factor: 11.082
Authors: Pieter J M Joosten; Chris Dickhoff; Vincent van der Noort; Maarten Smeekens; Rachel C Numan; Houke M Klomp; Judi N A van Diessen; Jose S A Belderbos; Egbert F Smit; Kim Monkhorst; Jan W A Oosterhuis; Michel M van den Heuvel; Max Dahele; Koen J Hartemink Journal: Interact Cardiovasc Thorac Surg Date: 2022-03-31
Authors: Nika Guberina; Lukas Kessler; Christoph Pöttgen; Maja Guberina; Martin Metzenmacher; Ken Herrmann; Maja Mucha; Christoph Rischpler; Frank Indenkämpen; Jens T Siveke; Jürgen Treckmann; Lale Umutlu; Stefan Kasper; Wolfgang P Fendler; Martin Stuschke Journal: Sci Rep Date: 2022-09-28 Impact factor: 4.996